Real-World Data of Tigecycline-Associated Drug-Induced Liver Injury Among Patients in China: A 3-year Retrospective Study as Assessed by the Updated RUCAM
Background: Tigecycline, a glycylcycline antibiotic, is increasingly used clinically for the treatment of severe infections caused by multidrug-resistant bacteria, but it is also associated with hepatotoxicity. However, the incidence and risk factors of tigecycline-associated drug-induced liver inju...
Main Authors: | Xiaoping Shi, Chengchun Zuo, Lingling Yu, Donghui Lao, Xiaoyu Li, Qing Xu, Qianzhou Lv |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-11-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2021.761167/full |
Similar Items
-
A case report of drug-induced liver injury after tigecycline administration: histopathological evidence and a probable causality grading as assessed by the updated RUCAM diagnostic scale
by: Xiaoping Shi, et al.
Published: (2022-04-01) -
Idiosyncratic DILI and RUCAM under One Hat: The Global View
by: Rolf Teschke, et al.
Published: (2023-08-01) -
Circulatory Inflammatory Mediators in the Prediction of Anti-Tuberculous Drug-Induced Liver Injury Using RUCAM for Causality Assessment
by: Cheng-Maw Ho, et al.
Published: (2021-07-01) -
Case report: Kinetics of human leukocyte antigen receptor HLA-DR during liver injury induced by potassium para-aminobenzoate as assessed for causality using the updated RUCAM
by: Marlene Plüß, et al.
Published: (2022-08-01) -
Liver Injury in COVID-19 Patients with Drugs as Causatives: A Systematic Review of 996 DILI Cases Published 2020/2021 Based on RUCAM as Causality Assessment Method
by: Rolf Teschke, et al.
Published: (2022-04-01)